Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease

doi:10.3748/wjg.v31.i48.114355

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 48

This Article

(39)

(49)

(0)

(1)

(1174)

(5)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 28, 2025; 31(48): 114355
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.114355

Full Size Figure Download Figure

Figure 1 Clinical activity in inflammatory bowel disease patients at 8-weeks prior, time of switch, and weeks 12 and 24 following biosimilar switching.

Citation: Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2025; 31(48): 114355
URL: https://www.wjgnet.com/1007-9327/full/v31/i48/114355.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i48.114355

Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2025; 31(48): 114355 [PMID: 41480329 DOI: 10.3748/wjg.v31.i48.114355]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.